OEL Fastrac Catalog

Please note, this OEL/ADE monograph also applies to 6-Methyluracil (CAS RN 626-48- 2), 5 - Methyluracil (CAS RN 65-71-4), 1-Methyluracil (CAS RN 615-77-0), and 3-Methyluracil (CAS RN 608-34-4). Uracil is a pyrimidine nitrogenous base (2,4-dioxypyrimidine), which is the essential part of the ribonucleic acid (RNA) nucleotide. Among the minor nitrogen bases, methyluracil is used in medical practice for its improvement of tissue metabolism and regeneration, its anabolic and anticatabolic effects, and its ability to activate leucopoiesis. Methyluracil is indicated for the treatment of proctitis, sigmoiditis, and ulcerative colitis. It is also indicated topically as an anti-inflammatory and immunostimulating drug that improves trophic tissues and stimulates regeneration. Methyluracil is also investigated as an anabolic immunomodulator and as an antiphlogistic in experimental diabetes in rats. Antiviral and antitumor activities are the two most widely reported activities of uracil analogues.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value, the acceptable surface limit (ASL), and the Permitted Daily Exposure (PDE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Methyluracil, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.